uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Recent trends on the role of epigenomics, metabolomics and noncoding RNAs in rationalizing mood stabilizing treatment
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Functional Pharmacology. Univ Cagliari, Sect Neurosci & Clin Pharmacol, Dept Biomed Sci, Cagliari, Italy.ORCID iD: 0000-0002-9151-4319
Univ Patras, Sch Hlth Sci, Dept Pharm, Patras, Greece.
Univ Patras, Sch Hlth Sci, Dept Pharm, Patras, Greece; United Arab Emirates Univ, Coll Med & Hlth Sci, Dept Pathol, Al Ain, U Arab Emirates.
Univ Cagliari, Sect Neurosci & Clin Pharmacol, Dept Biomed Sci, Cagliari, Italy; Dalhousie Univ, Dept Psychiat, Halifax, NS, Canada.
2018 (English)In: Pharmacogenomics (London), ISSN 1462-2416, E-ISSN 1744-8042, Vol. 19, no 2, p. 129-143Article, review/survey (Refereed) Published
Abstract [en]

Mood stabilizers are the cornerstone in treatment of mood disorders, but their use is characterized by high interindividual variability. This feature has stimulated intensive research to identify predictive biomarkers of response and disentangle the molecular bases of their clinical efficacy. Nevertheless, findings from studies conducted so far have only explained a small proportion of the observed variability, suggesting that factors other than DNA variants could be involved. A growing body of research has been focusing on the role of epigenetics and metabolomics in response to mood stabilizers, especially lithium salts. Studies from these approaches have provided new insights into the molecular networks and processes involved in the mechanism of action of mood stabilizers, promoting a systems-level multiomics synergy. In this article, we reviewed the literature investigating the involvement of epigenetic mechanisms, noncoding RNAs and metabolomic modifications in bipolar disorder and the mechanism of action and clinical efficacy of mood stabilizers.

Place, publisher, year, edition, pages
2018. Vol. 19, no 2, p. 129-143
Keywords [en]
carbamazepine, epigenetics, lithium, metabolomics, mood stabilizers, noncoding RNA, valproate
National Category
Pharmacology and Toxicology
Identifiers
URN: urn:nbn:se:uu:diva-357042DOI: 10.2217/pgs-2017-0111ISI: 000428950200006PubMedID: 29199496OAI: oai:DiVA.org:uu-357042DiVA, id: diva2:1238033
Available from: 2018-08-10 Created: 2018-08-10 Last updated: 2018-08-10Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Pisanu, Claudia

Search in DiVA

By author/editor
Pisanu, Claudia
By organisation
Functional Pharmacology
In the same journal
Pharmacogenomics (London)
Pharmacology and Toxicology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 2 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf